2-amino-1-methylcyclohexanol hydrochloride | 837377-78-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-amino-1-methylcyclohexanol hydrochloride
• 英文别名: 2-amino-1-methylcyclohexan-1-ol;hydrochloride
• CAS: 837377-78-3
• 化学式: C₇H₁₅NO*ClH
• 分子量: 165.663
• InChiKey: TWZWYKFAVZDTPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.06
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-fluoro-2-(3-methylsulphanyl-phenoxy)-nicotinic acid 、 2-amino-1-methylcyclohexanol hydrochloride 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 18.0h， 生成 5-fluoro-N-(2-hydroxy-2-methylcyclohexyl)-2-[3-(methylsulfanyl)phenoxy]nicotinamide
  参考文献：
  名称：

  [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  [FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4

  摘要：

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。

  公开号：

  WO2005009966A1
• 作为产物：
  描述：

  tert-butyl 2-hydroxy-2-methylcyclohexylcarbamate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 2-amino-1-methylcyclohexanol hydrochloride
  参考文献：
  名称：

  [EN] NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
  [FR] DERIVES DE NICOTINAMIDE AGISSANT COMME INHIBITEURS DE PDE4

  摘要：

  这项发明涉及式(I)的烟酰胺衍生物，以及含有该类衍生物的药物组合物，以及将这些衍生物用作PDE4抑制剂的用途，其中R7连接到苯环的3-或4-位，并且为S(O)pR8，R8为(C1-C4)烷基，可选择地被(C3-C6)环烷基取代；m为0或1；L为(C3-C8)非芳香环；其余变量如索权中所定义。

  公开号：

  WO2005009966A1

文献信息

• [EN] SELECTIVE ANDROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SÉLECTIFS D'UN RÉCEPTEUR DES ANDROGÈNES
  申请人：LILLY CO ELI

  公开号：WO2013055577A1

  公开（公告）日：2013-04-18

  The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

  本发明提供了新型选择性雄激素受体调节剂及其盐和药物组合物。
• Nicotinamide derivatives useful as PDE4 inhibitors
  申请人：Bailey Simon

  公开号：US20050032838A1

  公开（公告）日：2005-02-10

  This invention relates to nicotinamide derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing, and the uses of such derivatives: wherein R 1 is selected from the group consisting of hydrogen, methyl or halo; R 7 is attached to the 3- or 4-position of the phenyl ring and is S(O) p R 8 , R 8 is (C 1 -C 4 )alkyl optionally substituted by (C 3 -C 6 )cycloalkyl; p is 0, 1 or 2; R 6 is selected from the group consisting of hydrogen, halo, (C 1 -C 3 )alkyl and (C 1 -C 3 )alkoxy; m is 0 or 1; L is a (C 3 -C 8 )carbocyclic non-aromatic ring; R 2 is hydrogen, hydroxy, (C 1 -C 3 )alkoxy, (C 1 -C 3 )alkyl (optionally substituted by hydroxy or by (C 1 -C 3 )alkoxy), CO 2 R 9 , NR 10 R 11 or CONR 10 R 11 ; R 3 is hydrogen or (C 1 -C 3 )alkyl; R 9 is hydrogen or (C 1 -C 3 )alkyl; R 10 and R 11 are each independently hydrogen, or, are selected from the group consisting of: (C 1 -C 6 )alkyl optionally substituted by phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; (C 3 -C 8 )cycloalkyl; CO((C 1 -C 6 )alkyl) optionally substituted by hydroxy, halo, (C 3 -C 8 )cycloalkyl, (C 1 -C 3 )alkoxy, phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; CO(R 12 ), wherein R 12 is (C 3 -C 8 )cycloalkyl optionally substituted by (C 1 -C 3 )alkyl or R 12 is phenyl or a 5- or 6-membered heterocyclic ring incorporating 1 to 3 heteroatom(s) independently selected from N, O and S, which phenyl is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl or (C 1 -C 3 )alkoxy and which heterocyclic ring is optionally substituted by one or more subsituents selected from hydroxy, halo, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy or oxo; and CO 2 (C 1 -C 3 )alkyl); or R 10 and R 11 are taken together with the N atom to which they are attached to form a 5- or 6-membered lactam.

  本发明涉及化合物(I)的烟酰胺衍生物，以及制备这些衍生物的中间体的制备方法，含有这些衍生物的制药组合物，以及这些衍生物的用途：其中R1选自氢、甲基或卤素的群；R7附加到苯环的3-或4-位上，为S（O）pR8，R8为（C1-C4）烷基，可选地被（C3-C6）环烷基取代，p为0、1或2；R6选自氢、卤素、（C1-C3）烷基和（C1-C3）烷氧基的群；m为0或1；L为（C3-C8）非芳香环烷基；R2为氢、羟基、（C1-C3）烷氧基、（C1-C3）烷基（可选地被羟基或（C1-C3）烷氧基取代）、CO2R9、NR10R11或CONR10R11的群；R3为氢或（C1-C3）烷基；R9为氢或（C1-C3）烷基；R10和R11各自独立地选自以下群：（C1-C6）烷基，可选地被苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；（C3-C8）环烷基；CO（（C1-C6）烷基），可选地被羟基、卤素、（C3-C8）环烷基、（C1-C3）烷氧基、苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环取代，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；CO（R12），其中R12为（C3-C8）环烷基，可选地被（C1-C3）烷基取代，或R12为苯基或包含1至3个杂原子（独立选自N、O和S）的5-或6-成员杂环，其中苯基可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基或（C1-C3）烷氧基，而杂环可选地被一个或多个亚基选自羟基、卤素、（C1-C3）烷基、（C1-C3）烷氧基或氧代基；以及R10和R11一起与它们所附着的N原子形成5-或6-成员内酰胺。
• Selective Androgen Receptor Modulators
  申请人：Eli Lilly and Company

  公开号：US20130217762A1

  公开（公告）日：2013-08-22

  The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

  本发明提供了新型选择性雄激素受体调节剂及其盐和制药组合物。
• INDOL AND INDAZOL DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160207885A1

  公开（公告）日：2016-07-21

  The present invention relates to compounds of formula wherein A is R is lower alkyl, —(CH 2 ) z -C 3-7 -cycloalkyl or —(CH 2 ) z —C 4-6 -heterocycloalkyl, which are optionally substituted by one to three hydroxy, lower alkyl, lower alkoxy or halogen, or is (endo)-7-oxabicyclo[2.2.1]heptan-2-yl; X is CH or N; Y 1 is CR 3 or N; Y 2 is CR 4 ; or or Y 1 and Y 2 may form together with the carbon atoms to which they are attach Y 3 is N; Y 4 is N; Y 5 is NR 7 ; R 1 is hydrogen or halogen; R 2 is hydrogen, halogen, cycloalkyl, lower alkyl or lower alkoxy; R 3 is hydrogen, halogen, CN, —C(O)NH 2 , —C(O)NHCH 3 or —C(O)N(CH 3 ) 2 ; R 4 is hydrogen, a 5 or 6 membered heteroaryl or heterocyclyl group, selected from the group consisting of or is phenyl, —C(O)NH 2 , —CH 2 C(O)NH 2 , —C(O)NHCH 3 , —C(O)NH-cycloalkyl, —C(O)N(CH 3 ) 2 , —NHC(O)O-lower alkyl, CN, lower alkoxy, lower alkoxy substituted by halogen, halogen or S(O) 2 CH 3 ; R 5 is phenyl; R 6 is phenyl or thiazol-2-yl; R 7 is pyridin-2-yl or pyrimidin-4-yl; p is 0 or 1; m is 1, 2 or 3; z is 0 or 1; or a pharmaceutically acceptable acid addition salt, a racemic mixture or its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

  本发明涉及以下式子的化合物： 其中， A是 R是较低的烷基，-(CH2)z-C3-7-环烷基或-( )z-C4-6-杂环烷基，可选地被一个到三个羟基，较低的烷基，较低的烷氧基或卤素取代，或是(内)-7-氧杂双环[2.2.1]庚烷-2-基； X是CH或N； Y1是CR3或N； Y2是CR4；或 或Y1和Y2可以与它们所连接的碳原子一起形成； Y3是N； Y4是N； Y5是NR7； R1是氢或卤素； R2是氢，卤素，环烷基，较低的烷基或较低的烷氧基； R3是氢，卤素，CN，-C（O）NH2，-C（O）NH 或-C（O）N（CH3）2； R4是氢，5或6成员的杂芳基或杂环基，从以下组中选择，或是苯基，-C（O）NH2，- C（O）NH2，-C（O）NH ，-C（O）NH-环烷基，-C（O）N（ ）2，-NHC（O）O-较低的烷基，CN，较低的烷氧基，被卤素取代的较低的烷氧基，卤素或S（O）2 ； R5是苯基； R6是苯基或噻唑-2-基； R7是吡啶-2-基或嘧啶-4-基； p是0或1； m是1、2或3； z是0或1； 或其药学上可接受的酸加合物，外消旋体混合物或其对应的对映异构体。 这些化合物可用于治疗或预防阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍。
• PYRROLOPYRIDINE OR PYRAZOLOPYRIDINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20160194321A1

  公开（公告）日：2016-07-07

  The present invention relates to compounds of formula wherein R 1 halogen, lower alkyl, lower alkoxy, cyano, phenyl, C(O)NHCH 3 , C(O)NH 2 , lower alkyl substituted by halogen or is a five-membered heteroaryl group, optionally substituted by lower alkyl; Y 1 is N or CH; Y 2 is CH; and if Y 1 is CH, Y 1 and Y 2 may form together with the C-atoms to which they are attached a ring, containing —CH═N—N(CH 3 )—, —CH═N—N(H)—; X is CH or N; R is (CH 2 ) m -cycloalkyl, optionally substituted by hydroxy, lower alkoxy or lower alkyl, or is tetrahydropyran, optionally substituted by hydroxy, or is lower alkoxy, substituted by hydroxy, or is lower alkyl substituted by one or two hydroxy, or is (CH 2 ) m -pyridinyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, or is L-phenyl, optionally substituted by hydroxy, lower alkyl or lower alkyl substituted by hydroxy, and L is a bond, —CH(CH 2 OH)— or —CH 2 CH(OH)—; n is 0, 1 or 2; m is 0 or 1; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds of the present invention are muscarinic M1 receptor positive allosteric modulators (PAM) and hence are useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.

  本发明涉及式为的化合物，其中R1是卤素、较低的烷基、较低的烷氧基、氰基、苯基、C（O）NH 、C（O）NH2、被卤素取代的较低烷基或是一个五元杂环芳基基团，可选地被较低烷基取代；Y1是N或CH；Y2是CH；如果Y1是CH，则Y1和Y2可以与它们所连接的碳原子一起形成一个环，其中包含—CH═N—N（CH3）—，—CH═N—N（H）—；X是CH或N；R是（CH2）m-环烷基，可选地被羟基、较低烷氧基或较低烷基取代，或者是四氢吡喃，可选地被羟基取代，或是被羟基取代的较低烷氧基，或是被一或两个羟基取代的较低烷基，或是（ ）m-吡啶基，可选地被羟基、较低烷基或被羟基取代的较低烷基取代，或是L-苯基，可选地被羟基、较低烷基或被羟基取代的较低烷基取代，L是一个键、—CH（ OH）—或— CH（OH）—；n为0、1或2；m为0或1；或是其相应的对映体和/或光学异构体的药学上可接受的酸盐或其外消旋混合物。本发明的化合物是肌动蛋白M1受体正变构调节剂（PAM），因此在治疗由肌动蛋白M1受体介导的疾病，如阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍方面有用。